News

Neuropore Therapies and BenevolentAI Enter Strategic Collaboration to Discover Novel Therapeutics Through the Application of Artificial Intelligence

We have entered a collaboration with Neuropore Therapies, Inc to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.

We have entered a collaboration with Neuropore Therapies, Inc to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.The molecular targets of interest are implicated in dysfunctions in proteostasis and can therefore be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.

Errol De Souza, President and CEO of Neuropore, stated,

“We are very excited to establish this collaboration with BenevolentAI. The application of artificial intelligence to the elaboration of novel approaches to medicine is one of the leading edges of science and is an approach that is bound to lead to new discoveries. Neuropore’s Autophagy Platform is a perfect testing ground for new hypotheses and discoveries. In addition to its drug discovery capabilities, Neuropore’s development and translational experience in degenerative disease makes it a great fit for both companies.”

Anne Phelan, SVP BenevolentAI, said,

“The collaboration between Neuropore and BenevolentAI  offers a fantastic opportunity to accelerate the discovery of new medicines. Neuropore have built a world-leading platform for experimentally evaluating key processes within protein homeostasis, a critical biological mechanism in neurodegenerative diseases such as ALS. This system will allow the rapid and thorough evaluation of multiple novel targets, discovered using the BenevolentAI Platform, and enable us to validate new targets faster than ever."


For further information

Media Contact Neuropore:

Errol De Souza,

Ph.D.President & Chief Executive Officer

T +1 858-273-1831

Errol.DeSouza@neuropore.com

More Posts

You Might Also Like

News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Events
New tech brings new hope in our new normal | A Keynote from Joanna Shields at WeAreTechWomen
In this talk, Joanna Shields will demonstrate how human intelligence partnered with technology promises to accelerate new discoveries, new treatments, and new hope for patients.
Jun 26, 2020
Events
Transforming Biopharmaceutical Research with AI at The HESI Annual Meeting 2020.
Our Executive board director, Jackie Hunter, will take to the virtual stage to demonstrate how AI can be used right at the beginning of the R&D process to improve target identification and validation as well as being used to identify key pathways in disease
Jun 9, 2020
Video
How do we get the next 10 years right? | CogX Opening Keynote w/ Joanna Shields
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Events
Women in Biotech with Peju Oshisanya
Peju Oshisanya will join three other exceptional speakers from the biotech industry to discuss their personal journeys through research and biotechnology, also delving into their expertise on AI on how we can adopt this emerging technology to the benefit of biomedical research and how we can avoid the pitfalls.
Jun 4, 2020